AAL enters the final week of June with a rare alignment: short sellers are cutting exposure, analysts are chasing the stock higher with a wave of upgrades, and options traders are turning notably more defensive — all at the same time, and all in the same week.
The short-selling story is one of sustained retreat. Short interest has fallen nearly 20% over the past month, dropping to 9.4% of the free float — still meaningful, but well off the highs above 12% seen in mid-May. The pace accelerated this week, with shares short declining another 6.8% over five sessions. Borrow costs reflect the same trend: the cost to borrow has eased to just 0.33%, down roughly 17% from a month ago, touching the lowest level of the recent period. Crucially, the lending pool remains extremely loose. Availability is running at 1,334% — meaning there are roughly thirteen shares available to borrow for every one already lent out — a dramatic loosening from the 475% level seen in mid-May. The short score has also drifted lower, from 47.9 on June 10 to 44.6 now, suggesting the bearish pressure in the stock is genuinely unwinding rather than pausing.
Options tell a different story, and it's worth flagging the contrast. Despite the short-covering, the put/call ratio jumped to 1.86 on Tuesday — more than 2.6 standard deviations above its 20-day average of 1.69. That is the most defensive options positioning seen in the past month, and puts the ratio near the higher end of its 52-week range (low: 1.38, high: 2.41). Short sellers may be retreating, but options traders are hedging more aggressively than usual, perhaps wary of turbulence ahead of the Q2 print on July 22.
The Street has spent the past week lifting price targets across the board. Three bellwether firms moved in the past 48 hours alone: UBS raised its target from $18 to $21 while maintaining Buy, Bank of America lifted from $14 to $16 at Neutral, and Jefferies moved from $15 to $16 at Hold. Morgan Stanley had already moved to $24 (Overweight) earlier in June. The pattern is unanimous on direction — every recent action has been a raise — but divided on conviction, with bulls like UBS and Morgan Stanley seeing $21–$24 while more cautious voices cluster around $16. The consensus mean target is $15.86, roughly in line with the current $16.14 price, which suggests the Street is chasing rather than leading the rally. The EPS momentum factor score is striking: 30-day momentum ranks in the 99th percentile, even as the 90-day reading sits at just 4 — a whiplash reversal that likely reflects the Q2 guidance trim noted this week, which flagged weaker summer bookings and elevated fuel costs.
Peers moved in the same direction this week but AAL edged them out. UAL gained 1.3% on the week, DAL rose 3.2%, and JBLU added 3.2%, while AAL returned 2.7%. Smaller carriers had a better week — ULCC jumped 10.4% and ALGT gained 8.7% — but the context matters: those names carry more volatility and higher short interest pressure of their own.
The biggest institutional holder, PRIMECAP Management, added over 20 million shares in the latest reported period through May, lifting its stake to 10.5% of shares outstanding — a meaningful accumulation that gives the bull case some structural support. The insider picture is less encouraging: the CFO, COO, and CEO all sold in February and May, consistently at prices between $11.84 and $14.10. All of those sales were at levels well below the current price, so the signal is somewhat stale, but the pattern of consistent executive selling warrants monitoring.
The July 22 earnings report is the obvious next focal point — and given the Q2 guidance cut already in the market, what matters then is less the headline number and more whether management can restore confidence in the second-half demand outlook.
See the live data behind this article on ORTEX.
Open AAL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
